drugset / Trial / NCT04197310
Cabozantinib and Nivolumab for Carcinoid Tumors
Phase 2
Completed
19 enrolled
Dana-Farber Cancer Institute
Bristol-Myers Squibb · collabExelixis · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study, is studying the combination of cabozantinib and nivolumab in treating advanced carcinoid tumors. \- Carcinoid tumor is another term used to refer to neuroendocrine tumors that arise in organs such as the gastrointestinal tract, lungs, or thymus.
Timeline
- Start
- 2019-12-26
- Primary completion
- 2023-12-27
- Completion
- 2024-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 40 mg | Oral |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |